Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1055)
  3. Book Section (64)
  4. Review (64)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2694)
  2. Department of Medicine (2694)
  3. Hematologic Malignancies, Division of (2694)
  4. Population Sciences Research Program (742)
  5. Survivorship Research (654)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (664)
  3. Maria Palomba (443)
  4. Ariela Noy (369)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (41)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (277)
  3. Hematological Oncology (110)
  4. British Journal of Haematology (81)
  5. Leukemia and Lymphoma (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (293)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2694)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): Preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC)
    Meeting Abstract

    Noy, A.; Kaplan, L.; Lee, J.
    Blood (2009)

    Fulltext@MSK | Save
  • Rituximab, cyclophosphamide, bortezomib and prednisone (R-CBorP): Final results of a phase I trial evaluating two dosing schedules and the safety of overlapping pegfilgrastim in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C. S.; Hamlin, P. A.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Schulman, P.; Dumitrescu, O.; Sarasohn, D.; Pappanicholaou, J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Initial remission duration of less than 1 year is no longer an adverse prognostic factor for patients with relapsed HL undergoing high dose therapy and autologous stem cell transplant: Results of a combined analysis from two large transplant centers
    Meeting Abstract

    Moskowitz, A. J.; Sweetenham, J.; Bolwell, B. J.; Maragulia, J. C.; Vanak, J. M.; Moskowitz, C. H.; Smith, S.
    Blood (2009)

    Fulltext@MSK | Save
  • Stem cell transplant (SCT) and pralatrexate therapy: Outcome of patients with relapsed or refractory peripheral T-cell lymphoma who received SCT prior to or following pralatrexate therapy
    Meeting Abstract

    Popplewell, L.; Pro, B.; Jacobsen, E.; Horwitz, S. M.; Boyd, A.; Patterson, M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Multivalent DNA aptamer-based therapeutic agents for lymphoma and leukemia
    Meeting Abstract

    Mallikaratchy, P.; Ruggiero, A.; Maguire, W.; Piersanti, K.; Gardner, J.; Villa, C.; Escorcia, F.; Palomba, M. L.; Heaney, M.; McDevitt, M. R.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Negative interim FDG-PET scan is predictive of superior outcome in T cell lymphoma
    Meeting Abstract

    Casulo, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.
    Blood (2009)

    Fulltext@MSK | Save
  • Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results
    Meeting Abstract

    Horwitz, S. M.; Vose, J. M.; Advani, R.; Sankhala, K.; Padmanabhan, S.; Hamlin, P. A. Jr; Chen, A.; Zain, J. M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Safety and management of pralatrexate treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Pinter-Brown, L.; Horwitz, S. M.; Pro, B.; Zinzani, P. L.; Gisselbrecht, C.; Cortelli, B. M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Pralatrexate induces responses in patients with highly refractory peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Savage, K. J.; Shustov, A. R.; Goy, A.; Horwitz, S. M.; Pro, B.; Patterson, M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: Implications for vitamin prophylaxis
    Meeting Abstract

    Pro, B.; Coiffier, B.; Horwitz, S. M.; Boyd, A.; Neylon, E.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save